6th August，2019
— Can-Fite BioPharma Ltd. issued an announcement, which is summarized as
follows:
Can-Fite
BioPharma Ltd. announced that a supply of Namodenoson has been manufactured and
is ready for use in the treatment of advanced liver cancer patients under
compassionate use at the Rabin Medical Center in Israel.
Compassionate
use allows doctors and their patients the option of early access to
investigational new drugs, under closely controlled and monitored
circumstances, when a patient who is facing serious illness has exhausted all
available treatment options.
Salomon
M. Stemmer, MD, the Principal Investigator of the Company’s prior Phase II
liver cancer study said, “Given the evidence of clinical benefit of Namodenoson
in patients with hepatocellular carcinoma（HCC）
and Child Pugh B7 to whom there is no accepted well established treatment, I
plan to offer Namodenoson to certain HCC CPB7 patients in the compassionate use
setting.”
The original website link: